Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
暂无分享,去创建一个
S. Kopetz | Richard J Lee | D. Heimbrook | B. Higgins | K. Kolinsky | K. Packman | G. Bollag | M. Simcox | Hong Yang | B. Lestini | F. Su | K. Schostack | W. D. Bradley
[1] A. Hauschild,et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.
[2] K. Flaherty,et al. BRIM-2: An open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutation-positive metastatic melanoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] E. Van Cutsem,et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] R. Jorissen,et al. Optimizing targeted therapeutic development: Analysis of a colorectal cancer patient population with the BRAFV600E mutation , 2011, International journal of cancer.
[5] Y. Yatabe,et al. BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer , 2011, British Journal of Cancer.
[6] B. Trink,et al. The BRAFT1799A mutation confers sensitivity of thyroid cancer cells to the BRAFV600E inhibitor PLX4032 (RG7204). , 2011, Biochemical and biophysical research communications.
[7] M. Herlyn,et al. PLX4032, a potent inhibitor of the B‐Raf V600E oncogene, selectively inhibits V600E‐positive melanomas , 2010, Pigment cell & melanoma research.
[8] Kam Y. J. Zhang,et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma , 2010, Nature.
[9] K. Flaherty,et al. Inhibition of mutated, activated BRAF in metastatic melanoma. , 2010, The New England journal of medicine.
[10] J. Dering,et al. Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma. , 2010, Neoplasia.
[11] R. Radinsky,et al. Selective and Potent Raf Inhibitors Paradoxically Stimulate Normal Cell Proliferation and Tumor Growth , 2010, Molecular Cancer Therapeutics.
[12] D. Heimbrook,et al. RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. , 2010, Cancer research.
[13] P. Majumder,et al. MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo , 2010, Molecular Cancer Therapeutics.
[14] M. Duffy,et al. Activated Phosphoinositide 3-Kinase/AKT Signaling Confers Resistance to Trastuzumab but not Lapatinib , 2010, Molecular Cancer Therapeutics.
[15] J. Desai,et al. PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors. , 2010 .
[16] M. Belvin,et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth , 2010, Nature.
[17] Chao Zhang,et al. RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF , 2010, Nature.
[18] Michael Krauthammer,et al. PLX4032, a selective BRAFV600E kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAFWT melanoma cells , 2010, Pigment cell & melanoma research.
[19] J. Reis-Filho,et al. Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF , 2010, Cell.
[20] Linda Mol,et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. , 2009, The New England journal of medicine.
[21] M. Santoro,et al. Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells. , 2009, The Journal of clinical endocrinology and metabolism.
[22] A. Bardelli,et al. Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor–Targeted Therapy in Metastatic Colorectal Cancer , 2009, Journal of the National Cancer Institute.
[23] G. Fontanini,et al. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer , 2009, British Journal of Cancer.
[24] D. Heimbrook,et al. In vivo activity of novel capecitabine regimens alone and with bevacizumab and oxaliplatin in colorectal cancer xenograft models , 2009, Molecular Cancer Therapeutics.
[25] L. Mazzucchelli,et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] David B Solit,et al. Therapeutic strategies for inhibiting oncogenic BRAF signaling. , 2008, Current opinion in pharmacology.
[27] J. McCubrey,et al. Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors. , 2008, Current opinion in investigational drugs.
[28] Carlo Gambacorti-Passerini,et al. BRAF Silencing by Short Hairpin RNA or Chemical Blockade by PLX4032 Leads to Different Responses in Melanoma and Thyroid Carcinoma Cells , 2008, Molecular Cancer Research.
[29] G. Mills,et al. Improved classification of breast cancer by analysis of genetic alterations and gene expression profiling , 2011 .
[30] Stephen L. Abrams,et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. , 2007, Biochimica et biophysica acta.
[31] Jianping Chen,et al. Antitumor activity of HER1/EGFR tyrosine kinase inhibitor erlotinib, alone and in combination with CPT-11 (irinotecan) in human colorectal cancer xenograft models , 2007, Cancer Chemotherapy and Pharmacology.
[32] C. Johannessen,et al. A negative feedback signaling network underlies oncogene-induced senescence. , 2006, Cancer cell.
[33] B. Park,et al. Mutation of the PIK3CA oncogene in human cancers , 2006, British Journal of Cancer.
[34] T. Kawabe,et al. Functional analysis of PIK3CA gene mutations in human colorectal cancer. , 2005, Cancer research.
[35] Ming Zhou,et al. Regulation of Raf-1 by direct feedback phosphorylation. , 2005, Molecular cell.
[36] J. Sebolt-Leopold,et al. Targeting the mitogen-activated protein kinase cascade to treat cancer , 2004, Nature Reviews Cancer.
[37] Mathew J Garnett,et al. Guilty as charged: B-RAF is a human oncogene. , 2004, Cancer cell.
[38] B. Higgins,et al. Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models , 2004, Anti-cancer drugs.
[39] J. Ptak,et al. High Frequency of Mutations of the PIK3CA Gene in Human Cancers , 2004, Science.
[40] D. Barford,et al. Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF , 2004, Cell.
[41] K. Kinzler,et al. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status , 2002, Nature.
[42] A. Nicholson,et al. Mutations of the BRAF gene in human cancer , 2002, Nature.
[43] Philip R. Cohen,et al. Paradoxical activation of Raf by a novel Raf inhibitor. , 1999, Chemistry & biology.
[44] T. Mosmann. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.
[45] R. Weichselbaum,et al. Predictors of competing mortality in advanced head and neck cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] M. Gordon,et al. RG7204 (PLX4032), a Selective BRAFV600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models , 2010 .